Proviral activation of the Bmi1 gene has implicated Bmi1 as a collaborator of c-Myc in lymphomagenesis. To determine the eect of Bmi1 overexpression on hematopoiesis and lymphomagenesis transgenic mice were generated that overexpress dierent forms of the Bmi1 protein in their lymphoid compartment. EmBmi1 transgenic mice, overexpressing the wild type Bmi1 protein showed a perturbed lymphoid development and were highly susceptible to B and T cell lymphomagenesis. Mutational analysis of the Bmi1 protein demonstrated that the conserved N-terminal RING ®nger and central part of Bmi1 are essential for its oncogenic potential whereas the C-terminal Pro-Ser rich region is not required. We have used provirus tagging in the EmBmi1 mice to identify genes that cooperate with Bmi1 in lymphomagenesis. MoMLV infection in EmBmi1 transgenic mice accelerated lymphoma development. Proviral activation of the Pim and Myc genes but not the G®1 gene were frequently observed in these tumors. These results demonstrate that Bmi1 is a potent oncogene and suggest that it plays an important role in early lymphoid development.
Introduction
The Bmi1 gene was originally identi®ed as a common insertion site in Moloney Murine leukemia virus (MoMLV) induced B-cell lymphomas in EmMyc transgenic mice (Haupt et al., 1991; . Proviral integrations in the vicinity of the Bmi1 gene or in the more distant bla1 cluster result in the overexpression of Bmi1, suggesting that Bmi1 collaborates with c-Myc in lymphomagenesis. The Bmi1 gene encodes a 324 amino acids long nuclear phosphoprotein. The most noticeable protein motifs of Bmi1 include a zinc ®nger motif with a C 3 HC 4 consensus, termed RING ®nger (Saurin et al., 1996) , a putative helix ± turn ± helix ± turn ± helix ± turn (HTHTHT) (motif) and a C-terminal proline/serine rich region. The Bmi1 protein shares similarity with the Drosophila Polycomb group (Pc-G) protein Posterior Sex combs (Psc) and the related Suppressor-2 of Zeste (Su(z)2) Brunk et al., 1991) .
The conservation is particularly strong in the RING ®nger domain and a part of the HTHTHT motif suggesting a functional importance of these motifs. Members of the Drosophila Pc-G are required to maintain segment speci®c repression of homeotic genes throughout development (Simon, 1995) . We have shown previously that Bmi1 ful®lls a similar role in vertebrates. In parallel to Pc-G-loss-of-function mutants, Bmi1 null mutant mice show posterior transformation of the axial skeleton (van der Lugt et al., 1994) whereas transgenic mice that overexpress the Bmi1 gene during embryogenesis display anterior transformations . The skeletal transformations correlate with the shifts of several Hox gene expression boundaries which indicate that Bmi1 is involved in homeotic gene repression van der Lugt et al., 1996) . In accordance with an evolutionarily conserved function of Bmi1 in embryogenesis, we recently found that Bmi1 is a constituent of a multimeric protein complex containing proteins that share similarity with other Drosophila Polycomb members Gunster et al., 1997) .
Despite having been implicated in c-Myc mediated lymphomagenesis, direct evidence for the oncogenic potential of the Bmi1 gene is somewhat limited. Currently, one Bmi1 transgenic study has been reported on (Haupt et al., 1993) . In the single transgenic line examined in this study, the Bmi1 transgene was expressed at moderate levels in its lymphoid tissues, and although no abnormalities in lymphoid development were found, the transgenic line did exhibit a low incidence of spontaneous lymphomas. To study the eect of Bmi1 overexpression on hematopoiesis and lymphomagenesis in more detail we have also employed a transgenic mouse model system. In this report we show that EmBmi1 transgenic mice that overexpress the wild type Bmi1 protein in their lymphoid compartment develop lymphomas at high frequency. Preneoplastic analysis demonstrates that Bmi1 overexpression induces the expansion of early B and T cell populations. These results complement the observed reduction in B and T cell numbers in the Bmi1 null mutant mice (van der Lugt et al., 1994) and further demarcate the action of Bmi1 in lymphopoiesis. Mutational analysis of the Bmi1 transgene identi®ed the RING ®nger domain as one essential for the oncogenic potential of Bmi1. Furthermore, we used proviral tagging (for review see Jonkers and Berns 1996) in EmBmi1 transgenic mice to establish which genes collaborate with Bmi1 in tumor development. Analysis of proviral integration patterns demonstrates that Bmi1 eciently collaborates in lymphomagenesis with the Myc and Pim genes, but not the G®1 gene. The herein presented ®ndings ®rmly establish the role of Bmi1 in lymphomagenesis and implicate Bmi1 as a regulator of lymphopoiesis.
Results
EmBmi transgenic mice express the transgene at high levels in their lymphoid tissues
The transgenic constructs employed to overexpress wild type and mutant forms of the Bmi1 gene in the lymphoid compartment, consisted of mouse Bmi1 gene fragments linked to the Pim1 promoter, the immunoglobulin enhancer (Em) and Moloney murine leukemia virus (MoMLV) long terminal repeat (LTR) ( Figure  1a ). This promoter/enhancer combination has been shown to give high transgene expression during development and is active in both the B and T cell lineage (van Lohuizen et al., 1989) . A wild type EmBmi1 construct and three mutant constructs, EmBmiDP, EmBmiDH and EmBmiDZn, were made. The EmBmiDP construct (amino acids 1 ± 237) lacked the region of the Bmi1 gene that encodes the Pro/Ser rich region. The EmBmiDH encoded the Nterminal half of the Bmi1 protein, containing the conserved RING ®nger domain (amino acids 1 ± 333). The EmBmiDZn construct encoded a mutant Bmi1 protein in which two highly conserved cysteine residues of the RING ®nger were replaced by phenylalanine residues. Independent transgenic founders were obtained for each transgenic construct by standard procedures. Transgenic lines were established and checked for transgene expression. The EmBmi1-33 and -52, the EmBmiDP-29 and -40, the EmBmiDH-37 and EmBmiDZn-31 and -21 transgenic lines showed comparable transgene expression levels and were used for further analysis (Figure 1 ). Northern blot analysis of dierent tissues from mice of the EmBmi1-33 and EmBmi1-52 lines revealed two abundant transgenic transcripts in spleen, thymus and lung as compared to the low ubiquitous expression of the endogenous Bmi1 gene (Figure 1b) . High transgene expression in lung has also been observed in EmPim1 transgenic mice using the same promoter and enhancer elements. The two transcripts arise from the use of alternative polyadenylation sites in the Bmi1 3' untranslated region and the MoMLV LTR. As shown in Figure  1c similarly sized transgenic transcripts were highly expressed in spleen and thymus of the EmBmiDZn transgenic mice. The expected 1.4 kb and 1.1 kb and Bmi1 mutant transgenic transcripts were observed in the spleen and thymus of EmBmiDP and EmBmiDH transgenic mice, respectively (Figure 1c ). The dierent Bmi1 transgenic lines also expressed high levels of the transgene during embryonic development (Figure 1d ), which is in accordance with the embryonic transgene expression of the EmBmi1-33 and 52 line reported earlier .
Bmi1 overexpression induces the expansion of a CD4
+ thymocyte subset
To determine whether high levels of Bmi1 expression had any eect on the hematopoietic compartment of the EmBmi1-33 and -52 mice, spleen and thymus from 4 to 7 week old mice were examined histologically and nucleated cells were quanti®ed in peripheral blood and in cell suspensions of thymus, spleen and bone marrow.
No overt abnormalities were detected (data not shown).
In addition we analysed cell suspensions prepared from thymus and spleen by¯ow cytometry. 
CD8
7 pro-T cell subset, that expresses intermediate levels of the T cell maturation marker IL-2 receptor a chain (CD25) (Figure 2 ). T cell maturation does not appear to be aected since normal numbers of mature T cells expressing CD4 or CD8 were found in the spleen (data not shown). No clear abnormalities in the T cell populations in the thymus and spleen of mice of the EmBmiDZn, EmBmiDH and EmBmiDP transgenic lines were observed (data not shown).
It was previously shown that Bmi1 nullizygous mice are severely depleted of double positive and single positive thymocytes while the immature CD4 7 CD8 7 thymocytes are aected to a much lesser extent (van der Lugt et al., 1994) . This suggests that Bmi1 is important for the dierentiation of CD4 
+ thymocytes. We therefore, wanted to investigate the role of Bmi1 on early T cell development in more detail. Since the eect of Bmi1 overexpression on early T cell development might be obscured by the relatively small numbers of CD4
7

CD8
7 thymocytes in a wild type background, transgenic mice of the EmBmi1-33 line were back crossed with RAG1 mutant mice. RAG1 mutant mice are de®cient in V(D)J recombination and are consequently blocked in T cell development at the CD4 baerts et al., 1992) . Three color FACS analysis of thymocytes with the dierentiation markers CD4, CD8, CD5 and CD25 was used to determine whether early T cell dierentiation stages were aected in the EmBmi1 transgenic mice (Figure 2 ). EmBmi1 transgenic mice show an expansion of a CD4
7
CD8
7 pro-T cell subset, that expresses intermediate levels of the T cell maturation marker CD5 and IL-2 receptor a chain (CD25). Overexpression of Bmi1 on a RAG1 de®cient background resulted in a 3-fold increase in the number of thymocytes (Table 1 ). Flow cytometric analysis shows that the increased thymic cellularity was a consequence of a 50-fold increase in the number of CD4
+ pro-T cells. These pro-T cells constituted 81% of the thymocytes in the EmBmi1/ RAG17/7 mice compared to 5% in the RAG17/7 mice. The expansion of the CD4 The expansion of the early T cell subset in the EmBmi1 transgenic mice is most clearly observed in the RAG17/7 background. Since we have not analysed the thymic T cell populations of the mutant Bmi1 transgenic mice in a RAG1 mutant background we can 1o population also expressed the HSA and the Bp-1 pre-B cell markers. In the spleen normal amounts of mature B cells were found, although the B220 cell surface expression remained low compared Figure 2 Eects of Bmi1 overexpression on thymocyte development. FACS analysis of wild type, EmBmi1-33 transgenic, RAG17/ 7 and EmBmi1-33/RAG1 7/7 thymocytes was performed. Thymocytes were triple-stained with saturating amounts of FITCconjugated CD4-speci®c mAb, PE-conjugated CD8-speci®c mAb and either biotin-conjugated CD25-or CD5-speci®c mAb. Indicated are the total number and percentage of thymocytes, the number of CD25-, CD25+ and CD25++ double negative thymocytes in RAG1 7/7 and EmBmil-33/RAG1 7/7mice as determined by¯ow cytometry. The increase in total cell numbers in the EmBmil1 ± 33/RAG1 7/7 compared to RAG1 7/7 littermates is due to the expansion of a CD4-CD8-CD25+CD5+ pro-T cell subset (see also Fig .2) to wild type. A reduced B220 staining was also observed for B cells in the bone marrow and spleen of the EmBmiDP-40 transgenic mice. B cell populations and the B220 cell surface expression in bone marrow and spleen were unaected in the EmBmiDH-37 and EmBmiDZn-31 transgenic mice (data not shown). The reason for the low B220 staining in the EmBmi1 and EmBmiDP transgenic mice is unclear but it could be a relic of an early dierentiation state. The EmBmi1 transgene did not lead to any changes in the B220 1o population in the RAG17/7 background but did induce a Bp-1 + B220 7 population which is normally not detected in the bone marrow of RAG17/7 mice or wild type mice (data not shown). The relevance of this population is unclear.
EmBmi1 transgenic mice are predisposed to B and T cell lymphomagenesis
Both the EmBmi1-33 and EmBmi1-52 transgenic line developed lymphomas very rapidly (Figure 4 ). The latency period of tumor development was similar to that observed for the EmMyc transgenic mice (Adams et al., 1985) but was considerably shorter than for the previously described EmBmi1-3 transgenic line (Haupt et al., 1993) . Although the EmBmi1-33 line succumbed to lymphomas a little faster than the EmBmi1-52 line, no dierences were observed in pathology or tumor cell types in both strains. Three other primary EmBmi1 transgenic mice developed lymphomas within 130 days without giving rise to transgenic ospring. Autopsy of the diseased mice revealed dierent pathologies. One group of mice (43%) displayed a dramatically enlarged thymus and in half of these cases an enlarged spleen. Another group (51%) had an enlarged spleen and lymph nodes. A small fraction (6%) showed both pathologies. Tumors were analysed by¯ow cytometry for lineage speci®c markers. The thymic tumors were of T cell origin. 1o/+ ). The occurrence of both B and T cell tumors in mice of the EmBmi1-33 and EmBmi1-52 transgenic lines correlates with the perturbed B and T cell development in these mice. All tumors that were analysed expressed high levels of the EmBmi1 transgene. While some of the spontaneous tumors that were analysed showed an elevated Pim1 expression (6/16), all tumors expressed the c-Myc gene at high levels (16/16) (data not shown). Southern blot analysis indicated that the c-Myc activation in these tumors was not the result of translocation, as observed in most plasmacytomas of the Em-v-Abl mice (Rosenbaum et al., 1990) . Injection of tumor cells of three dierent lymphomas into syngeneic hosts caused secondary tumors after a latency of 2 ± 4 weeks.
The Bmi1 RING ®nger is required for its oncogenic potential
In order to identify the functional domains in the Bmi1 protein important for lymphoid transformation the None of the mice of the EmBmiDH-37 line, that overexpressed the N-terminal half of the Bmi1 protein, developed lymphomas over a period of 15 months, nor did mice from the EmBmiDZn-21 line, which overexpressed a Bmi1 RING ®nger mutant protein ( Figure  4) . One of 19 mice of the EmBmiDZn-31 line developed a lymphoma at the age of 287 days. It is not clear whether this lymphoma is a consequence of the transgene expression or a spontaneous lymphoma, sometimes seen at low frequency in the FVB strain. Western blot analysis ascertained that Bmi1 RING ®nger mutant protein levels in the EmBmiDZn lines were comparable to Bmi1 levels in the EmBmi1-33 line (data not shown). The Bmi1 antisera are directed against the C-terminal half of the Bmi1 protein and do not recognize the BmiDH and BmiDP protein. Although the comparable phenotypes of the EmBmi1 and EmBmiDP transgenic mice indicate that the BmiDP protein is being produced, we cannot fully exclude that the C-terminal truncation aects stability of the BmiDH protein which might obscure the phenotypic eects in the EmBmiDH-37 line. In conclusion, these experiments show that for a high incidence of lymphomas in EmBmi transgenic mice, the N-terminal RING ®nger and, most likely, an internal region including the HTHTHT motif of Bmi1 are required, whereas the C-terminal Pro/Ser region of Bmi1 is dispensable.
MoMLV infection accelerates B and T cell lymphomagenesis in EmBmi1 transgenic mice
Proviral tagging (for review see Jonkers and Berns, 1996) was used to establish which genes collaborate with Bmi1 in lymphomagenesis. New-born ospring from crossings between heterozygous EmBmi1-33 and wild type mice were therefore infected with MoMLV. As shown in Figure 5 , the average latency of tumorigenesis was reduced from 85 days for the infected wild type mice to 63 days for the EmBmi1-33 transgenic litter mates. Both in the wild type and EmBmi1 transgenic mice, MoMLVinduced disease results in enlargement of the spleen, most lymph nodes and the thymus, often with the concomitant lymphoblast tissue in®ltration. Infection of wild type FVB mice with MoMLV results exclusively in the induction of T cell lymphomas . FACS analysis showed that most (9/11) of the tumors induced in the EmBmi1 transgenic mice were of T cell origin, being either CD4 ).
Bmi1 cooperates with the Myc and Pim oncogenes but not the G®1 gene in MoMLV-induced lymphomagenesis
Southern blot analysis of 13 MoMLV accelerated EmBmi1-33 and 16 normal lymphomas showed that the tumors contained four to 15 proviral inserts. To determine whether known oncogenes were activated by proviral integration, we screened the tumors by Southern blot analysis with probes from genes previously implicated in MoMLV-induced lymphomagenesis. Not surprisingly, a signi®cant fraction of the tumors of the EmBmi1-MoMLV panel harbored proviral insertions within the c-Myc (2/13) or N-Myc (3/13) locus ( Figure  6 ). The Pim1 (3/13) and Pim2 (1/13) genes were found to be activated by proviral integrations in four tumors. The tic1 locus, a proviral integration cluster implicated in tumor progression (Breuer et al., 1989) , was rearranged in two tumors. The G®1 locus (the combined eis-1/pas1/evi5 loci) maps to a 50 kb chromosomal region which is frequently rearranged in MoMLV-induced pre-B and T cell lymphomas (Scheijen et al., 1997; Gilks et al., 1993; Liao et al., 1995) . In the MoMLV-induced EmBmi1 tumors no rearrangements in the locus were detected while only one of 13 tumors contained a subclonal integration of the G®1 (eis1) locus ( Figure 6 ). In contrast, nearly half of the wild type tumors contained a clonal integration in the G®1 locus (pal1 4/16; evi5 3/16). This suggests that if the Bmi1 gene in activated, proviral activation of the G®1 gene no longer gives a selective growth advantage to the cell. These results further substantiate the notion that Bmi1 and G®1 belong to the same complementation group in lymphoid transformation Scheijen et al., 1997) . 
Discussion
Bmi1 overexpression perturbs lymphoid development
CD25
++ pro-thymocyte subset in RAG1 mutant mice. This assumption is further supported by previous observations indicating that the developmental transition from CD25 ++ to CD25 7 pre-T cells proceeds through a CD25 + intermediate stage (Shinkai and Alt, 1994; Jacobs et al., 1994) . These data indicate that Bmil overexpression promotes both the proliferation and the dierentiation of pro-T cells.
Bone marrow analysis of EmBmi1 transgenic mice revealed an expansion of a pre-B cell population expressing the Bp-1 HSA and low levels of the B220 lineage markers. These pre-B cells normally mature to sIg + B cells, although B220 cell surface expression remains dull, and are found in normal numbers in the periphery. The low B220 staining of the expanded pre-B cell compartment in the EmBmi1 transgenic mice might indicate an aberrant dierentiation and increased proliferation of even earlier progenitor cells. The lymphoid phenotype of the EmBmi1 transgenic mice further demarcates the action of Bmi1 in lymphoid development and is in accordance with the complementary phenotype observed in the Bmi17/7 mice (van der Lugt et al., 1994) . Although the number of B and T cells of all maturation stages are signi®cantly reduced in Bmi7/7, pro-B cells (B220 + CD43 + ) and 
CD8
7 T cells are aected to a lesser extent. Taken together, the results indicate that Bmi1 function is of particular importance for the dierentiation and proliferation pro-B and pro-T cells (Figure 7 ).
Bmi1 induced lymphomagenesis and cooperation with other oncogenes
EmBmi1 transgenic mice developed B and T cell lymphomas very rapidly, providing direct evidence for the strong oncogenic potential of the Bmi1 gene. The rate of tumor onset of the EmBmi1 lines described here is considerably faster than for the previously reported EmBmi1-3 line (Haupt et al., 1993) . This dierence is most likely the result of the higher transgene expression levels in our transgenic lines.
While the development of B cell lymphomas was anticipated from the proviral activation of Bmi1 in pre-B cell lymphomas (Haupt et al., 1991; , it is surprising that EmBmi1 transgenic mice are also predisposed to T cell lymphomagenesis. Although the Bmi1 gene serves as a common insertion site in feline leukemia virus (FeLV) induced T cell lymphomas in cats (Levy et al., 1993) As observed for transgenic mouse strains carrying other oncogenes, EmBmi1 transgenic mice develop lymphomas after a variable latency period, indicating that Bmi1 overexpression is not sucient for lymphoma development. Proviral tagging in the EmBmi1 transgenic mice showed that Bmi1 synergizes with the Pim and Myc genes in lymphomagenesis. Intercrosses of EmMyc and EmBmi1 mice yielded very few bitransgenic ospring. The two that were obtained developed pre-B cell lymphomas within 35 days. These results are reminiscent of the strong collaborative action of the EmMyc and EmPim1 transgene which resulted in the development of pre-B cell leukemias in utero . An accelerated onset of lymphomagenesis was also observed upon cross breeding EmBmi1-3 mice and EmMyc mice (Haupt et al., 1993) . Taken together these results demonstrate a strong collaboration between Bmi1 and c-Myc in tumor development. What could be the basis of this strong collaboration between c-Myc and Bmi1? EmMyc mice have a considerably enlarged pre-B cell compartment due to an increased proliferation rate of pre-B cells concomitant with an impaired dierentiation (Harris et al., 1988; Langdon et al., 1986) . It has been shown that high c-Myc expression correlates with both increased proliferation and with increased apoptosis (Evan et al., 1992) suggesting that cell death is an important limitation in c-Myc mediated transformation. The synergy of c-Myc and the anti-apoptotic Bcl2 gene in lymphomagenesis supports this notion (Vaux et al., 1988; Strasser et al., 1990) . In contrast to thymocytes that overexpress Bc12 (Sentman et al., 1991; Strasser et al., 1991) however, the response to dexamethasone and DNA damage induced apoptosis was unchanged in EmBmi1 thymocytes (H. Brady, personal communica- Figure 7 The role of Bmi1 in T and B cell development. Dierentiation antigens that demarcate the various stages of lymphocyte dierentiation are indicated. Broken lines indicate that lineage relationships during early lymphoid development are unresolved. The rearrangement status of the T-cell receptor (TCR) and B-cell receptor (BCR) heavy chain are depicted. In the RAG1 7/7 mice lymphocyte dierentiation is blocked at the early pre-T and early pre-B cell stage. Thick arrows indicate the developmental transitions that are promoted by Bmi1. At these stages increased proliferation and/or dierentiation is observed in the EmBmi1 transgenic mice whereas a decrease in proliferation and/or dierentation is observed in the Bmi1 7/7 mice tion) suggesting that Bmi1 is not protecting cells from apoptosis. In view of the aberrations seen in Bmi1 transgenic mice, the pre-B cell compartment in an EmMyc/EmBmi1 background might be further expanded, increasing the likelihood of accumulating additional oncogenic mutations in these cells. One of the predominant MoMLV proviral insertion sites is the G®1 locus (the combined eis-1/pal1/evi5 loci) (ZoÈ rnig et al., 1996; Gilks et al., 1993; Liao et al., 1995; Scheijen et al., 1997) . Mostly clonal integrations are found in more than 90% of the EmPim1 and 75% of the H-2KMyc-induced T cell lymphomas and 24% of B cell lymphomas induced in EmMyc mice (J. Allen personal communication; Scheijen et al., 1997) . Most proviral integrations in this locus correlated with enhanced transcription of the G®1 gene making it the best candidate oncogene in the locus. Interestingly, of 155 MoMLV-induced EmMyc tumors analysed in our laboratory, only four (3%) harbored proviral insertions in both the Bmi1 (71/155, 46%) and G®1 (37/155, 24%) locus (Scheijen et al., 1997; J Allen, personal communication; . This is far fewer than would be expected on the basis of the proviral activation frequency of the individual loci (P50.001 by w square test). This suggests that Bmi1 and G®1 act on the same or similar downstream targets for lymphoid transformation. The EmBmi1 MoMLV-induced tumors reinforce this notion, since only a single subclonal integration in the G®1 locus was found in this panel. Endogenous expression levels of G®1 were unchanged in EmBmi1 transgenic mice, excluding the possibility that Bmi1 induces G®1 expression (data not shown). Unlike the constituents of the Pim and Myc complementation groups, the Bmi1 and zinc ®nger protein, G®1 (Gilks et al., 1993) are unrelated.
Functional domains of the Bmi1 protein
Using transgenic mice that overexpress mutant forms of the Bmi1 protein we have identi®ed some of the functional domains of Bmi1 important to lymphomagenesis. The Bmi1 protein harbors two domains which are conserved in the Drosophila Psc and Su(z)2 proteins: a RING ®nger domain at the N-terminus of the protein, and a putative HTHTHT motif at a central portion of protein (Brunk et al., 1991; . The high lymphoma incidence of transgenic mice that overexpress the C-terminally truncated version of the Bmi1 protein demonstrates that the Pro/Ser rich region of the Bmi1 protein is not required for its transforming potential. However, overexpression of a mutant Bmi1 protein with a Cterminal deletion that also aects the conserved HTHTHT motif did not predispose to lymphomagenesis. Induction of lymphomas was also abolished if the Bmi1 RING ®nger is mutated. Thus the Bmi1 RING ®nger is essential but not sucient for lymphoma induction. It was recently shown that the Bmi-1 RING ®nger is also required for the transformation of Rat 1a cells (Cohen et al. 1996) . The molecular function of the RING ®nger is unclear at present. It is unlikely that the RING ®nger is involved in direct DNA binding since it clearly diers from classical DNA binding zinc ®ngers (Barlow et al., 1994; Borden et al., 1995) and has been identi®ed in a diverse set of proteins including those exclusively found in the cytoplasm (for review see Saurin et al., 1996) . We have shown that the Bmi1 RING ®nger is required for localization of Bmi1 to distinct subnuclear domains in interphase nuclei of U-2 OS cells . Also the RING ®nger motifs of the acute promyelocytic leukemia associated protein PML (Kastner et al., 1992; Borden et al., 1995) and herpes simplex virus Vmw110 protein (Everett et al., 1995) are required for localization to subnuclear structures. These PML containing structures however do not overlap with those containing Bmi1 . These data favor a role for the RING ®nger domain in protein-protein interactions. This is further supported by the ®nding that a region of the BRCA1 protein encompassing a RING ®nger domain is important for the interaction with another RING ®nger protein BARD1 (Wu et al., 1996) . Whether the localization of Bmi1 to the subnuclear structures is essential for its transforming capacity remains to be established.
Pc-G function and lymphomagenesis
We have shown previously that Bmi1 is involved in the repression of Hox genes during embryogenesis van der Lugt et al., 1996) . Hox genes are also widely expressed in the hematopoietic system and are thought to regulate dierentiation or proliferation of hematopoietic cell lineages (Lawrence and Largman, 1992) . Homeobox genes, like the HOX11 (Dube et al., 1991; Hatano et al., 1991) , HOXA-9 (Borrow et al., 1996; Nakamura et al., 1996a, b) and Hoxb-8 gene (Kongsuwan et al., 1989) , have been implicated in human and murine leukemias. This raises the question of whether the predisposition to lymphomagenesis of the EmBmi1 transgenic mice is a consequence of deregulated Hox gene expression patterns. The role of Bmi1 in Hox gene regulation during development was anticipated by the function of its counterpart in Drosophila, the Pc-G member Psc. It is important to note however, that Drosophila Pc-G proteins not only regulate the expression of Hox genes but are also involved in the regulation of other genes (McKeon et al., 1994; Pelegri and Lehmann, 1994) . This is illustrated by the fact that, beside the homeotic cluster genes, the Pc-G proteins localize to a large number of sites on the polytene chromosomes of the salivary gland (Rastelli et al., 1993) . Moreover,¯ies that are mutant for individual Pc-G members often display non overlapping pleiotropic phenotypes suggesting that in addition to the shared regulation of homeotic gene expression, individual Pc-G members may have separate targets. Although we cannot exclude at this point that the oncogenic capacity of Bmi1 is mediated through the deregulation of Hox gene expression patterns, there is some indirect evidence which argues against this view. We have also analysed mice of the dierent mutant Bmi1 transgenic lines for malformations of the axial skeleton (Figure 8) . Surprisingly, EmBmiDZn mice, which do not develop lymphomas, do display anterior transformation of the axial skeleton comparable to that in the EmBmi1 mice . This suggests that the Bmi1 RING ®nger is not essential for Pc-G function, but mediates protein-protein interaction with regulators of lymphoid development. Alternatively, the Bmi1 RING ®nger might be important for the speci®city of Pc-G complex for a particular subset of lymphoid target genes. The dierent eect on the lymphoid and skeletal phenotype in the EmBmiDZn mice does indicate that predisposition to lymphomagenesis involved deregulation of other genes than those aected by Bmi1 overexpression during embryonic development. In support of this, no dierences in the levels of Hoxc-5 expression were observed in lymphomas with wild type or high expression of Bmi1 (EmBmi1) (data not shown), although Hoxc-5 expression boundaries are aected in EmBmi1 embryos. Furthermore, one might expect that other murine Polycomb members can contribute to lymphoid transformation as well, considering the cooperative action of Pc-G proteins in Drosophila. Northern blot analysis and analysis of proviral integration patterns of MoMLV-induced tumors in the EmMyc and EmBmi1 transgenic mice have so far not provided evidence for activation of three other murine Polycomb members (M van Lohuizen and M Alkema, unpublished results): Mel18 which is closely related to Bmi1 (Akasaka et al., 1996) , M33 (Pearce et al., 1992 (Pearce et al., 1992 or Mph1/Rae28 Nomura et al., 1994) .
The skeletal phenotype and lymphoid phenotype might therefore represent dierent aspects of Bmi1 function. The EmBmi1 transgenic mice described in this study will facilitate dissecting the interaction of Bmi1 with lymphoid target genes which should lead to its mechanisms of action in lymphoid development and transformation.
Materials and methods
Generation of transgenic mice
The generation of the EmBmi1 transgenic mice has been described . For the EmBmiDH construct a BssHII/HIII genomic Bmi1 fragment was cloned in a transgene vector linking the Bmi1 gene to the Pim1 promoter, the immunoglobulin heavy chain enhancer (Em) and a MoMLV long terminal repeat (LTR). The EmBmiDH construct was elongated with a HIII ± BstXI fragment from a murine Bmi1 cDNA to generate the EmBmiDP construct. A NsiI ± SacI Bmi1 genomic fragment containing exon 2 and 3 was used for PCR mediated mutagenesis using the 5'-CCATAATAGAATTCCTACAT-TCCT-3', 5'-GAATTC-TATTATGGTAGTGGC-3' (exon 2) and 5'-CTATTTC-TAGTTTTAAAACATGTATTG-3', 5'-AAGACTAGAAA TAGGAACATAAACGG-3' (exon 3) as primers. The EmBmiDZn construct was made by replacing NsiI ± SacI fragment from the EmBmi1 construct by the corresponding mutated fragment. A puri®ed SalI fragment was used for micro injection into FVB fertilized oocytes as previously described. The RAG1 de®cient mice have been described (Mombaerts et al., 1992) . Bmi1 transgenic mice were crossed with RAG1 de®cient mice. Transgenic ospring was further crossed with RAG1 mutant mice. The resulting transgenic and non-transgenic heterozygous and homozygous RAG1 mutant mice were used for FACS analysis at an age of 5 weeks. RAG1 de®cient mice were kept in isolators under SPF conditions.
MoMLV infection
One to three days old mice from EmBmi1-336FVB crossing were injected with 2.5610 5 infectious units of Moloney Murine Leukemia Virus (Jaenisch et al., 1975) and monitored for the development of tumors. Mice were sacri®ced when the mice became terminally ill and tumor tissues were frozen at 7808C. Single-cell suspension of lymphomas were analysed by¯ow cytometry.
DNA and RNA analysis
Transgenic mice and embryos were identi®ed by Southern blotting EcoRi digested tail or extra embryonic tissue DNA, isolated and hybridized as described . The dierent male EmBmi1 transgenic mice were mated overnight with wild type female FVB mice. Animals that had a vaginal plug at noon the next day were considered as 0.5 d.p.c. High molecular weight DNA was prepared from tissues and tumors as described (Laird et al. 1991) including one phenol step. For Southern blotting 15 mg genomic DNA was digested with restriction enzymes as recommended by the supplier (Boehringer), transferred to Hybond (Amersham). Genotyping of RAG1 de®cient mice has been described (Mombaerts et al., 1992) . For Northern blot analysis 15 mg of total RNA, isolated by the LiC1-urea method, was separated on 1% agarose formaldehyde gels, transferred to Hybond (Amersham). Proviral rearrangements were detected by Southern blot analysis with 32 P-labelled probes previously described (van der . Northern blots were performed with a Bmi1 cDNA ORF probe (NsiI ± PvuII fragment.
Antibodies and¯ow cytometry
Cell suspensions of lymphoid organs and tumors were prepared by mincing the tissue through a nylon mesh (Falcon). For the analysis of the pre-neoplastic stage 2 to 3 mice per transgenic line were analysed and compared with wild type control littermates. Single cells were kept at 48C in RPMI medium and the numbers of nucleated cells was determined with an automated cell counter (Sysmex Toa F800). Approximately 5610 5 cells were incubated in 96-well V-bottom plates (Greiner) for 30 min at 48C in 20 ml PBA (16PBS, 0.5% BSA and 0.05% sodium azide) and saturating amounts of monoclonal antibodies. Cells were washed twice with PBA. Cells incubated with biotinconjugated mAb were subsequently either stained by incubation with PE-conjugated strept-avidin (double stainings) or by incubation with cychrome-conjugated streptavidin (triple stainings). After washing twice,¯ow cytometry was performed on a FACScan (Becton Dickinson, Mountain View, CA), using Lysis II software. Data are depicted as dot plots. The mAbs anti CD45R/B220 (6B2), anti BP-1 (6C3), anti CD43 (S7), mouse-anti-rat kappa light chain, anti-CD3e (145-2C11), anti-CD4 (RM4-5), anti-CD5 (53-7.3), anti-CD8 (53-6.7), anti-CD25 (7D4), anti-HSA (clone M1/69) and anti-TCRb (H57-597) were purchased from Pharmingen (San Diego, CA), sIg/goat anti mouse immunoglobulin from TAGO, Burlingame, CA. FITC-, PE-and/or biotin-conjugates thereof were used for immuno¯uorescence.
